The document is an investor presentation by Antares Pharma discussing its business and growth strategy. It summarizes that Antares has a diversified revenue mix from proprietary, partner, and development products. It achieved $184 million in revenue in 2021 and guides to $200-220 million in 2022. It is focusing on urology and endocrinology areas with innovative products like XYOSTED and NOCDURNA. XYOSTED is an once weekly testosterone injection that has seen growing prescription trends. The presentation outlines Antares' strategy to expand partnerships and its proprietary product portfolio to drive continued financial growth.
Kamada - Q42023 Results Presentation - March 2024KAMADA
Kamada held an investors meeting to discuss its financial results and growth outlook. Kamada achieved its 2023 revenue guidance of $142.5 million and adjusted EBITDA of $24.2 million. It expects double-digit revenue and profitability growth in 2024 to a range of $156-160 million in revenues and $27-30 million in adjusted EBITDA. Kamada has 6 FDA-approved plasma products and is pursuing additional plasma collection centers in the US. It is also conducting a Phase 3 trial of an inhaled alpha-1 antitrypsin treatment for AAT deficiency, targeting a potential $1 billion market.
Zomedica is revolutionizing veterinary health care with a focus on addressing unmet needs through its expanding product portfolio of innovative diagnostics and medical devices designed to improve pet health as well as productivity and practice profitability for veterinarians. With modest cash burn and a strong balance sheet, including $158.5 million cash, cash equivalents, and available-for-sale securities as of September 30, 2022, Zomedica is well-positioned to fund both organic growth and acquisitions. The Company’s current product portfolio includes: TRUFORMA® - in-clinic diagnostics with canine and feline assays; TRUVIEW® - innovative digital imaging technologies; VetGuardian® - wireless remote monitoring of vital signs; Assisi® tPEMF® - targeted pulsed electromagnetic field therapy; PulseVet® - global market leader in shock wave therapy in equine and small animal market.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
The document discusses Glaukos Corporation's portfolio of micro-scale injectable glaucoma therapies and products in development. It summarizes key 2017 accomplishments including clinical trials, new product submissions, and international expansion. The document outlines Glaukos' vision to address the full range of glaucoma disease states with novel surgical and pharmaceutical therapies, highlighting the iDose travoprost intraocular drug delivery implant currently in Phase II clinical trials. Glaukos aims to deliver five new U.S. product introductions between 2018-2023 to transform glaucoma treatment.
Glaukos march 2018 ir presentation 03012018glaukos
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' product portfolio including the iStent, pipeline of micro-scale injectable therapies like iStent inject and iDose travoprost implant. It summarizes Glaukos' 2017 financial and operational performance including revenue growth, expansion into new markets, and progress advancing its product pipeline. The document positions Glaukos to address the full range of glaucoma disease states with its portfolio of MIGS and beyond therapies.
Novartis announced a new organizational model to power its next phase of innovation, growth, and productivity. Key elements include:
1) Integrating Pharma and Oncology into a single Innovative Medicines business with separate US and International units to increase focus and drive synergies.
2) Combining strategy, portfolio management, and business development into a new Strategy & Growth function to strengthen the pipeline.
3) Forming a single Operations unit and integrating global G&A functions to realize economies of scale and productivity gains.
The changes aim to make Novartis more competitive, enhance operational efficiencies, and deliver high value medicines to support consistent above-peer growth.
60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting COVID-19, fungal, tick-borne, and other viral diseases.
Kamada - Q42023 Results Presentation - March 2024KAMADA
Kamada held an investors meeting to discuss its financial results and growth outlook. Kamada achieved its 2023 revenue guidance of $142.5 million and adjusted EBITDA of $24.2 million. It expects double-digit revenue and profitability growth in 2024 to a range of $156-160 million in revenues and $27-30 million in adjusted EBITDA. Kamada has 6 FDA-approved plasma products and is pursuing additional plasma collection centers in the US. It is also conducting a Phase 3 trial of an inhaled alpha-1 antitrypsin treatment for AAT deficiency, targeting a potential $1 billion market.
Zomedica is revolutionizing veterinary health care with a focus on addressing unmet needs through its expanding product portfolio of innovative diagnostics and medical devices designed to improve pet health as well as productivity and practice profitability for veterinarians. With modest cash burn and a strong balance sheet, including $158.5 million cash, cash equivalents, and available-for-sale securities as of September 30, 2022, Zomedica is well-positioned to fund both organic growth and acquisitions. The Company’s current product portfolio includes: TRUFORMA® - in-clinic diagnostics with canine and feline assays; TRUVIEW® - innovative digital imaging technologies; VetGuardian® - wireless remote monitoring of vital signs; Assisi® tPEMF® - targeted pulsed electromagnetic field therapy; PulseVet® - global market leader in shock wave therapy in equine and small animal market.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
The document discusses Glaukos Corporation's portfolio of micro-scale injectable glaucoma therapies and products in development. It summarizes key 2017 accomplishments including clinical trials, new product submissions, and international expansion. The document outlines Glaukos' vision to address the full range of glaucoma disease states with novel surgical and pharmaceutical therapies, highlighting the iDose travoprost intraocular drug delivery implant currently in Phase II clinical trials. Glaukos aims to deliver five new U.S. product introductions between 2018-2023 to transform glaucoma treatment.
Glaukos march 2018 ir presentation 03012018glaukos
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' product portfolio including the iStent, pipeline of micro-scale injectable therapies like iStent inject and iDose travoprost implant. It summarizes Glaukos' 2017 financial and operational performance including revenue growth, expansion into new markets, and progress advancing its product pipeline. The document positions Glaukos to address the full range of glaucoma disease states with its portfolio of MIGS and beyond therapies.
Novartis announced a new organizational model to power its next phase of innovation, growth, and productivity. Key elements include:
1) Integrating Pharma and Oncology into a single Innovative Medicines business with separate US and International units to increase focus and drive synergies.
2) Combining strategy, portfolio management, and business development into a new Strategy & Growth function to strengthen the pipeline.
3) Forming a single Operations unit and integrating global G&A functions to realize economies of scale and productivity gains.
The changes aim to make Novartis more competitive, enhance operational efficiencies, and deliver high value medicines to support consistent above-peer growth.
60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting COVID-19, fungal, tick-borne, and other viral diseases.
- Frexalimab demonstrated significantly reduced disease activity in relapsing multiple sclerosis in a phase 2 trial, meeting its primary endpoint with an 89% reduction in new gadolinium-enhancing lesions. It was well tolerated across all dose arms. Pivotal trials are planned to start in 2024.
- Amlitelimab showed statistically significant improvements in atopic dermatitis symptoms compared to placebo in a phase 2b trial. Biomarker results support effects on both type 2 and non-type 2 inflammation pathways. It was well tolerated. Pivotal trials are planned for 2024.
- A phase 1b trial of SAR443765, an IL-13/TSL
- Sanofi reported Q2 2023 results with total sales up 3.3% driven by double-digit growth of Specialty Care led by Dupixent and strong growth in Vaccines, while CHC was impacted by a Q1 inventory build.
- Specialty Care sales increased 11.8% led by 34.2% growth of Dupixent which saw demand-driven growth across its five approved indications. Rare Diseases grew 9.6% mainly due to patient accruals in Fabry and Pompe franchises and the strong launch of Nexviazyme. Neurology, Oncology and Rheumatology declined 35.1% due to LOE impact on Aubagio.
-
Impax provides an overview of its growth strategy, operations, generic and branded businesses, and 2014 financial outlook. The company's growth strategy focuses on internal and external R&D opportunities, M&A, and business development to drive revenue growth. Key generic products launched in 2013 include oxymorphone ER and authorized generics of Zomig and Trilipix. The branded pipeline includes RYTARY for Parkinson's disease and a bupivacaine patch for postherpetic neuralgia. For 2014, Impax forecasts adjusted gross margins in the low 50% range and expenses of $82-88M for generic R&D and $36-39M for branded R&D.
Genetic Technologies is an Australian company focused on developing and commercializing genetic risk assessment tests. The presentation provides an overview of the company's business, including its portfolio of current and upcoming genetic tests, markets and channels to market, and capabilities. Key points include:
- Genetic Technologies aims to offer the most comprehensive suite of genetic risk assessment tests on the market, covering up to 70% of disease risks.
- The company is prioritizing market entry strategies in key regions like Australia, the US, and Asia.
- Tests are marketed through consumer-initiated and medical business-to-business channels.
- An innovative pipeline of new tests for diseases like cancer, heart disease, and diabetes is being
Impax third quarter 2017 earnings call presentation impax-labs
Impax reported third quarter 2017 results and provided a business update. Key points include:
- Revenues declined year-over-year due to lower generic pricing, but increased sequentially driven by cost savings initiatives. Adjusted EBITDA and EPS also increased quarter-over-quarter.
- Generic division revenues declined year-over-year due to lower pricing, partially offset by higher volumes. Pricing declines moderated sequentially. The specialty pharmaceutical division saw revenue growth driven by higher product sales.
- Phase 2b results for Parkinson's treatment IPX203 showed significant reduction in "off time" compared to an immediate-release competitor, supporting advancement to Phase 3.
- Impax remains on track or ahead of
Sanofi reported its Q4 and full year 2022 results with strong growth. The document discusses Sanofi's strategy execution which delivered growth and margin expansion through 2022. It provides an agenda for the investor relations presentation covering a business update on specialty care, vaccines, GenMed and consumer healthcare performance in Q4 2022 as well as the financial performance and outlook for 2023.
- Sanofi reported Q1 2022 results with sales growth of 8.6% and earnings per share growth of 16.1%.
- Dupixent sales increased 45.7% driven by strong performance across indications.
- Vaccines sales grew 6.8% led by pertussis-containing vaccines in China and higher sales of travel and endemic vaccines.
- The company advanced its pipeline during the quarter with regulatory submissions and trials across core therapeutic areas.
BLFS Investor Presentation January 2024.pdftberard
BioLife Solutions is a leading bioproduction tools and services provider for cell and gene therapy markets. It has a portfolio of biopreservation media, cold chain management products, and cell processing tools used in 14 approved cell and gene therapies worldwide. BioLife is well positioned in the fast-growing cell and gene therapy market. It is divesting its freezer businesses in 2024 to improve its financial profile and focus on high margin, recurring revenue streams from its core cell processing and storage platforms.
Sharps Technology is a medical device company addressing global issues while engineering a safer future for healthcare providers and people everywhere through compassionate innovation. Sharps’ line of smart safety syringes eliminates accidental needlestick injuries, prevents needle reuse, and reduces wasted vaccines and medicine while retaining the intuitive simplicity of traditional syringes. Sharps Technology aims to be a solution provider for the advancement of future drug delivery systems.
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
- Amlitelimab, an investigational IRAK4 degrader, showed significant improvements in signs and symptoms of atopic dermatitis in a Phase 2b trial. At week 16, 40.3% of patients achieved EASI-75 with amlitelimab vs 11.4% with placebo, and 22.1% achieved IGA 0/1 vs 5.1% with placebo.
- At week 24, amlitelimab continued to show benefits over placebo with 54.5% achieving EASI-75 vs 17.7% for placebo, and 45.5% achieving IGA 0/1 vs 11.4% for placebo.
- Amlitelimab
- Q2 2022 sales were $11.9 billion, up 2% year-over-year and up 5% excluding foreign exchange effects. Double-digit earnings per share growth was achieved in Q2.
- Key pipeline milestones included Breyanzi receiving approval for 2L DLBCL in the US and positive phase 2 data for milvexian in secondary stroke prevention.
- The acquisition of Turning Point Therapeutics, expected to close in Q3 2022, will broaden the oncology portfolio with the potential best-in-class ROS1 inhibitor repotrectinib.
The document is a presentation from Impax Laboratories' management at the Cowen and Company 34th Annual Health Care Conference on March 3, 2014.
In 3 sentences:
1) Impax Laboratories has leveraged its dual generic and brand business model and significant investments to drive 21% revenue growth over 7 years and create resources for business development and M&A.
2) The company is focused on growing its generic and brand pipelines through internal R&D, partnerships, and M&A, while continuing to implement a quality improvement program and commercialize new products.
3) Impax provided 2014 objectives including resolving its manufacturing warning letter, commercializing potential new generics, resubmitting its RYTARY N
Impax Laboratories Credit Suisse 2013 Healthcare Conference November 14, 2013impax-labs
1) The document contains a "Safe Harbor Statement" noting that statements in the presentation contain forward-looking information and are subject to risks and uncertainties.
2) It discusses Impax Laboratories' positioning for future growth through its generic and branded platforms, established core competencies, and strong financial profile.
3) It provides an overview of Impax's two growth platforms - generics and brands, noting key areas of focus and pipeline products for each.
Cangene provides forward-looking statements that are subject to risks and uncertainties. The company's businesses are subject to risks that cannot be predicted or quantified, so past results may differ from future results expressed or implied in forward-looking statements. The document discusses various risks and uncertainties that could affect the company's results.
Impax reported its fourth quarter and full year 2016 financial results. Revenue declined year-over-year due to continued pricing pressures and volatility in the generic drug market. The company reported a net loss for the year due to non-cash impairment charges related to intangible assets. Looking ahead, Impax expects the challenging market conditions to continue but believes its specialty drug portfolio and generic pipeline can drive growth. Key priorities for 2017 include reducing debt, improving efficiency, and investing in R&D and generic launches.
Shire - The Path to US$10 Billion in Product Sales by 2020Company Spotlight
Shire outlines a plan to achieve $10 billion in product sales by 2020 through 10% compound annual growth rate. This will be achieved through growth of existing products, pipeline programs currently in development becoming commercialized, and potential additional M&A and licensing deals. Key elements of the plan include simplifying the organizational structure to focus on four commercial business units and one integrated R&D unit, improving operational efficiency through a cost savings program, and acquiring new products like Lifitegrast for dry eye disease and Maribavir for CMV infection in transplant patients. Shire believes this strategy will allow it to maintain leadership in rare diseases and deliver substantial shareholder value through 2020 and beyond.
The document provides an overview of Novartis' Q1 2022 results, including growth drivers, financial performance, and priorities for 2022. It notes that in Q1 2022, Novartis saw sales growth of 5% with Innovative Medicines sales up 4%. Key growth drivers like Cosentyx, Entresto, and Zolgensma had double-digit sales increases. The presentation discusses pipeline progress and expectations for continued mid-term growth.
Impax laboratories credit suisse conference nov 11 2014impax-labs
Impax provides a summary of its dual generic and branded business model, focusing on resolving FDA issues, maximizing both platforms, optimizing R&D, and accelerating business development. It highlights recent generic and branded product launches contributing over $190 million and the growth of Zomig Nasal Spray sales. Impax also outlines its reorganization of R&D to strengthen infrastructure, leverage internal strengths, improve efficiencies, and prioritize quality initiatives within scientific operations.
The document provides an overview of the pharmaceutical R&D pipeline in 2022, including key trends and statistics. Some of the main points summarized are:
- The total drug development pipeline grew by 8.2% in 2022 to over 20,000 drugs, with most growth occurring in early stages. Cancer remains the dominant therapeutic area.
- 2021 saw a record number of new drug launches, with 97 new active substances approved. Cancer drugs accounted for many novel launches, along with treatments for COVID-19, autoimmune diseases, and other areas.
- The top 10 pharmaceutical companies by pipeline size saw little change, with Novartis, Roche, and Takeda maintaining the top spots. Cancer remains
Natco Pharma Limited is an integrated pharmaceutical company with operations across India, the US, and rest of world. It has a strong brand presence in oncology in India and is growing its portfolio in cardiology and diabetes. The company focuses on complex generics for the US market through niche Paragraph IV and Paragraph III filings. It has two R&D centers with over 525 employees and is poised for growth in the agricultural chemicals space. For the financial year ending March 2021, Natco Pharma reported total revenues of INR 21,557 million.
More Related Content
Similar to Antares_Investor_Presentation_March_2022.pdf
- Frexalimab demonstrated significantly reduced disease activity in relapsing multiple sclerosis in a phase 2 trial, meeting its primary endpoint with an 89% reduction in new gadolinium-enhancing lesions. It was well tolerated across all dose arms. Pivotal trials are planned to start in 2024.
- Amlitelimab showed statistically significant improvements in atopic dermatitis symptoms compared to placebo in a phase 2b trial. Biomarker results support effects on both type 2 and non-type 2 inflammation pathways. It was well tolerated. Pivotal trials are planned for 2024.
- A phase 1b trial of SAR443765, an IL-13/TSL
- Sanofi reported Q2 2023 results with total sales up 3.3% driven by double-digit growth of Specialty Care led by Dupixent and strong growth in Vaccines, while CHC was impacted by a Q1 inventory build.
- Specialty Care sales increased 11.8% led by 34.2% growth of Dupixent which saw demand-driven growth across its five approved indications. Rare Diseases grew 9.6% mainly due to patient accruals in Fabry and Pompe franchises and the strong launch of Nexviazyme. Neurology, Oncology and Rheumatology declined 35.1% due to LOE impact on Aubagio.
-
Impax provides an overview of its growth strategy, operations, generic and branded businesses, and 2014 financial outlook. The company's growth strategy focuses on internal and external R&D opportunities, M&A, and business development to drive revenue growth. Key generic products launched in 2013 include oxymorphone ER and authorized generics of Zomig and Trilipix. The branded pipeline includes RYTARY for Parkinson's disease and a bupivacaine patch for postherpetic neuralgia. For 2014, Impax forecasts adjusted gross margins in the low 50% range and expenses of $82-88M for generic R&D and $36-39M for branded R&D.
Genetic Technologies is an Australian company focused on developing and commercializing genetic risk assessment tests. The presentation provides an overview of the company's business, including its portfolio of current and upcoming genetic tests, markets and channels to market, and capabilities. Key points include:
- Genetic Technologies aims to offer the most comprehensive suite of genetic risk assessment tests on the market, covering up to 70% of disease risks.
- The company is prioritizing market entry strategies in key regions like Australia, the US, and Asia.
- Tests are marketed through consumer-initiated and medical business-to-business channels.
- An innovative pipeline of new tests for diseases like cancer, heart disease, and diabetes is being
Impax third quarter 2017 earnings call presentation impax-labs
Impax reported third quarter 2017 results and provided a business update. Key points include:
- Revenues declined year-over-year due to lower generic pricing, but increased sequentially driven by cost savings initiatives. Adjusted EBITDA and EPS also increased quarter-over-quarter.
- Generic division revenues declined year-over-year due to lower pricing, partially offset by higher volumes. Pricing declines moderated sequentially. The specialty pharmaceutical division saw revenue growth driven by higher product sales.
- Phase 2b results for Parkinson's treatment IPX203 showed significant reduction in "off time" compared to an immediate-release competitor, supporting advancement to Phase 3.
- Impax remains on track or ahead of
Sanofi reported its Q4 and full year 2022 results with strong growth. The document discusses Sanofi's strategy execution which delivered growth and margin expansion through 2022. It provides an agenda for the investor relations presentation covering a business update on specialty care, vaccines, GenMed and consumer healthcare performance in Q4 2022 as well as the financial performance and outlook for 2023.
- Sanofi reported Q1 2022 results with sales growth of 8.6% and earnings per share growth of 16.1%.
- Dupixent sales increased 45.7% driven by strong performance across indications.
- Vaccines sales grew 6.8% led by pertussis-containing vaccines in China and higher sales of travel and endemic vaccines.
- The company advanced its pipeline during the quarter with regulatory submissions and trials across core therapeutic areas.
BLFS Investor Presentation January 2024.pdftberard
BioLife Solutions is a leading bioproduction tools and services provider for cell and gene therapy markets. It has a portfolio of biopreservation media, cold chain management products, and cell processing tools used in 14 approved cell and gene therapies worldwide. BioLife is well positioned in the fast-growing cell and gene therapy market. It is divesting its freezer businesses in 2024 to improve its financial profile and focus on high margin, recurring revenue streams from its core cell processing and storage platforms.
Sharps Technology is a medical device company addressing global issues while engineering a safer future for healthcare providers and people everywhere through compassionate innovation. Sharps’ line of smart safety syringes eliminates accidental needlestick injuries, prevents needle reuse, and reduces wasted vaccines and medicine while retaining the intuitive simplicity of traditional syringes. Sharps Technology aims to be a solution provider for the advancement of future drug delivery systems.
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
- Amlitelimab, an investigational IRAK4 degrader, showed significant improvements in signs and symptoms of atopic dermatitis in a Phase 2b trial. At week 16, 40.3% of patients achieved EASI-75 with amlitelimab vs 11.4% with placebo, and 22.1% achieved IGA 0/1 vs 5.1% with placebo.
- At week 24, amlitelimab continued to show benefits over placebo with 54.5% achieving EASI-75 vs 17.7% for placebo, and 45.5% achieving IGA 0/1 vs 11.4% for placebo.
- Amlitelimab
- Q2 2022 sales were $11.9 billion, up 2% year-over-year and up 5% excluding foreign exchange effects. Double-digit earnings per share growth was achieved in Q2.
- Key pipeline milestones included Breyanzi receiving approval for 2L DLBCL in the US and positive phase 2 data for milvexian in secondary stroke prevention.
- The acquisition of Turning Point Therapeutics, expected to close in Q3 2022, will broaden the oncology portfolio with the potential best-in-class ROS1 inhibitor repotrectinib.
The document is a presentation from Impax Laboratories' management at the Cowen and Company 34th Annual Health Care Conference on March 3, 2014.
In 3 sentences:
1) Impax Laboratories has leveraged its dual generic and brand business model and significant investments to drive 21% revenue growth over 7 years and create resources for business development and M&A.
2) The company is focused on growing its generic and brand pipelines through internal R&D, partnerships, and M&A, while continuing to implement a quality improvement program and commercialize new products.
3) Impax provided 2014 objectives including resolving its manufacturing warning letter, commercializing potential new generics, resubmitting its RYTARY N
Impax Laboratories Credit Suisse 2013 Healthcare Conference November 14, 2013impax-labs
1) The document contains a "Safe Harbor Statement" noting that statements in the presentation contain forward-looking information and are subject to risks and uncertainties.
2) It discusses Impax Laboratories' positioning for future growth through its generic and branded platforms, established core competencies, and strong financial profile.
3) It provides an overview of Impax's two growth platforms - generics and brands, noting key areas of focus and pipeline products for each.
Cangene provides forward-looking statements that are subject to risks and uncertainties. The company's businesses are subject to risks that cannot be predicted or quantified, so past results may differ from future results expressed or implied in forward-looking statements. The document discusses various risks and uncertainties that could affect the company's results.
Impax reported its fourth quarter and full year 2016 financial results. Revenue declined year-over-year due to continued pricing pressures and volatility in the generic drug market. The company reported a net loss for the year due to non-cash impairment charges related to intangible assets. Looking ahead, Impax expects the challenging market conditions to continue but believes its specialty drug portfolio and generic pipeline can drive growth. Key priorities for 2017 include reducing debt, improving efficiency, and investing in R&D and generic launches.
Shire - The Path to US$10 Billion in Product Sales by 2020Company Spotlight
Shire outlines a plan to achieve $10 billion in product sales by 2020 through 10% compound annual growth rate. This will be achieved through growth of existing products, pipeline programs currently in development becoming commercialized, and potential additional M&A and licensing deals. Key elements of the plan include simplifying the organizational structure to focus on four commercial business units and one integrated R&D unit, improving operational efficiency through a cost savings program, and acquiring new products like Lifitegrast for dry eye disease and Maribavir for CMV infection in transplant patients. Shire believes this strategy will allow it to maintain leadership in rare diseases and deliver substantial shareholder value through 2020 and beyond.
The document provides an overview of Novartis' Q1 2022 results, including growth drivers, financial performance, and priorities for 2022. It notes that in Q1 2022, Novartis saw sales growth of 5% with Innovative Medicines sales up 4%. Key growth drivers like Cosentyx, Entresto, and Zolgensma had double-digit sales increases. The presentation discusses pipeline progress and expectations for continued mid-term growth.
Impax laboratories credit suisse conference nov 11 2014impax-labs
Impax provides a summary of its dual generic and branded business model, focusing on resolving FDA issues, maximizing both platforms, optimizing R&D, and accelerating business development. It highlights recent generic and branded product launches contributing over $190 million and the growth of Zomig Nasal Spray sales. Impax also outlines its reorganization of R&D to strengthen infrastructure, leverage internal strengths, improve efficiencies, and prioritize quality initiatives within scientific operations.
Similar to Antares_Investor_Presentation_March_2022.pdf (20)
The document provides an overview of the pharmaceutical R&D pipeline in 2022, including key trends and statistics. Some of the main points summarized are:
- The total drug development pipeline grew by 8.2% in 2022 to over 20,000 drugs, with most growth occurring in early stages. Cancer remains the dominant therapeutic area.
- 2021 saw a record number of new drug launches, with 97 new active substances approved. Cancer drugs accounted for many novel launches, along with treatments for COVID-19, autoimmune diseases, and other areas.
- The top 10 pharmaceutical companies by pipeline size saw little change, with Novartis, Roche, and Takeda maintaining the top spots. Cancer remains
Natco Pharma Limited is an integrated pharmaceutical company with operations across India, the US, and rest of world. It has a strong brand presence in oncology in India and is growing its portfolio in cardiology and diabetes. The company focuses on complex generics for the US market through niche Paragraph IV and Paragraph III filings. It has two R&D centers with over 525 employees and is poised for growth in the agricultural chemicals space. For the financial year ending March 2021, Natco Pharma reported total revenues of INR 21,557 million.
The document provides an investor presentation for Sun Pharmaceutical Industries Limited. It summarizes Sun Pharma's position as the 4th largest global specialty generic company, with a presence in over 100 countries. It outlines Sun Pharma's long-term strategy of enhancing its specialty business portfolio and achieving differentiation through complex products. The presentation provides details on Sun Pharma's revenue composition, history of growth and acquisitions, operations, and financial performance.
Roche and Genentech are leading healthcare companies dedicated to innovation in a sustainable way. Roche was founded in 1896 in Basel and still has majority family ownership. It has over 100,000 employees worldwide and sales of 62.8 billion CHF in 2021. Roche invests heavily in R&D and healthcare and was among the top companies in the Dow Jones Sustainability Index for 13 consecutive years. Genentech was the first publicly-owned biotech company. Roche has a unique innovation model with independent research centers worldwide and global product development, manufacturing, and commercialization. It manages over 250 partnerships and is optimally positioned as the leader in personalized healthcare through diagnostics, therapies, and decision support. Roche Partnering has
Mayne Pharma announced the proposed sale of its Metrics Contract Services business for US$475 million. The sale will allow Mayne Pharma to focus on building its dermatology and women's health product portfolios. Mayne Pharma intends to use the majority of the sale proceeds to repay debt and return excess funds to shareholders through initiatives like a capital return or special dividend. The sale is expected to strengthen Mayne Pharma's balance sheet and financial flexibility.
The document provides updates from Managed Health Services (MHS), an Indiana Medicaid health plan, including:
- COVID-19 policy changes have been rescinded and MHS will reimburse providers for COVID-19 vaccine counseling.
- MHS offers daily inpatient and discharge reports, and weekly medical and prescription claims reports to help providers monitor their patients.
- Provider incentives are offered for activities like pregnancy notifications and smoking cessation counseling.
- Changes to prior authorization requirements for outpatient behavioral health therapy now follow a calendar year limitation.
- MHS encourages coordination between behavioral and physical health providers and offers related training.
- New provider enrollment requests and additions to existing contracts will now be effective
This document is an investor presentation for AMN Healthcare that provides an overview of the company. Some key points:
- AMN Healthcare is a leader and innovator in total talent solutions for healthcare, providing staffing, workforce solutions, leadership and physician search, and talent management services.
- Over 60% of AMN's revenue comes from managed services programs (MSPs) where they provide comprehensive staffing and workforce solutions to health systems.
- AMN has transformed from primarily a diversified staffing company in 2008 to a strategic partner providing a full spectrum of innovative workforce solutions to major health systems in 2022.
- They aim to become the total talent solutions partner for clients by enhancing their digital
The DESTINY-Breast04 trial is a Phase III randomized trial evaluating Enhertu compared to chemotherapy for previously treated HER2-low metastatic breast cancer. The trial randomized over 550 patients 2:1 to receive either Enhertu or one of several standard chemotherapy options. The primary endpoint is progression-free survival in the hormone receptor positive subgroup. Key secondary endpoints include overall survival in both the hormone receptor positive and total patient populations. Baseline characteristics were well balanced between the two arms. Results from this trial could establish Enhertu as a new treatment option for HER2-low breast cancer.
The document provides information from the 2022 DHA Industry Day, including:
- A list of requirements presented by different DHA directorates, such as medical logistics, enterprise medical services, administration and management, and information operations.
- The agenda for the industry day, including opening remarks, office briefings, and presentations from various DHA directorates.
- A discussion of the Defense Health Agency's transition and optimization efforts, including establishing markets, certifying market offices, realigning military treatment facilities, and pursuing ongoing market and DHA optimization.
- Healius reported record underlying results for 1H 2022 underpinned by Pathology's role in COVID testing and good cost control.
- The company is positioned for growth as routine healthcare demand rebounds from underdiagnosis during the pandemic. COVID testing volumes are also expected to remain at baseline levels.
- A strong interim dividend was declared and the company has a robust balance sheet to fund further growth opportunities like the Agilex Biolabs acquisition and Murdoch Day Hospital development.
Tenet Healthcare's CEO presented at the J.P. Morgan Healthcare Conference on January 11, 2022. Over the past several years, Tenet has transformed its portfolio, restructured operations, and improved quality and safety outcomes. It has demonstrated resiliency during the COVID-19 pandemic by consistently meeting or beating quarterly earnings guidance. Tenet aims to continue this growth trajectory by enhancing specialty care access, scaling its ambulatory surgery platform, and leading new high acuity services in lower cost settings.
Apollo Hospitals Enterprise Limited is a leading private healthcare services provider in India with over 6 decades of operations. It operates 71 hospitals with close to 10,000 beds across India and has expanded access to affordable healthcare through various initiatives. Apollo has played a pivotal role in developing the private healthcare sector in India by improving clinical outcomes and attracting medical talent both from India and overseas. Going forward, the company aims to continue its growth through a focus on clinical excellence, digital healthcare, and expansion into underserved markets.
Novo Nordisk presented highlights from the first six months of 2022. Their diabetes value market share increased 1.5 percentage points to 31%. Obesity care sales grew 84% driven by GLP-1 and insulin growth. They aim to further innovation in diabetes treatment, obesity, and rare diseases. Financial results were positive with 16% sales growth, 14% operating profit growth, and DKK 42.7 billion in free cash flow.
1) This training presentation provides guidance to research coordinators on clinical trial data collection and management best practices.
2) It reviews key definitions like source documents and case report forms, the lifecycle of developing a data management plan, and tips for proper documentation.
3) Ensuring data integrity involves accurate data entry from source documents to case report forms by coordinators, with oversight from principal investigators and monitoring by sponsors to meet regulatory standards.
This document outlines the key sections and content of a medical research paper, including reporting guidelines. It discusses sections like the title, abstract, introduction, methods, results, discussion, and conclusions. The methods section should describe the study design, participants, interventions, outcomes, and statistical analysis. The results section should report answers to the study questions using text, tables, and figures. The discussion should interpret the findings in the context of other research and discuss implications and recommendations. Reporting guidelines provide standards for transparently reporting different types of studies and their methodology.
1) The document provides tips for writing a high quality medical research paper, including how to structure the paper and what content to include in each section.
2) Key sections of a research paper are outlined, including the Introduction, Methods, Results, and Discussion sections. Guidance is given on what information should be included in each section.
3) Advice is given on writing clearly and concisely, using proper formatting, and focusing on quality over quantity. Following guidelines for target journals and ethical writing standards is emphasized.
Omega Healthcare Investors is a healthcare REIT that owns and leases skilled nursing and senior housing facilities. This presentation provides an overview of Omega's portfolio, strategy, and the skilled nursing facility industry. The key points are:
1) Omega has a large, geographically diversified portfolio of 939 healthcare properties across 43 U.S. states and the UK, leased to 63 different operators under long-term triple net leases.
2) Skilled nursing facilities provide essential healthcare services and meet an increasing demand from an aging population within a regulated industry with barriers to new supply growth.
3) Omega focuses on maintaining a conservative balance sheet, consistent dividend growth, and pursuing accretive investment opportunities to
The document is a Q2 FY18 investor presentation for HealthCare Global Enterprises Limited. Some key points:
- Q2 revenue grew 21.3% year-over-year to INR 2,111 million driven by growth in HCG and Milann centers.
- Q2 EBITDA increased 22.3% to INR 311 million with margins of 14.7%. Existing centers saw an EBITDA margin of 18.8%.
- New centers commissioned after April 2015 contributed revenues of INR 314 million but remained loss-making in Q2.
- GE is planning to spin off its healthcare business to become a standalone company called GE HealthCare in early January 2023.
- GE HealthCare is a global leader in medical technologies and digital solutions with over $18B in annual revenue and operations in over 160 countries.
- As an independent company, GE HealthCare aims to accelerate revenue growth, expand margins to a high-teens to 20% range through business optimization, and generate strong free cash flow to create sustainable long-term shareholder value.
The document discusses Joint Commission International (JCI) accreditation. It provides information on what accreditation is, the benefits of accreditation, and an introduction to JCI. Some key points include:
- Accreditation is a voluntary process where an independent entity assesses a healthcare organization against set standards to improve safety and quality.
- Benefits of accreditation include improving public trust, establishing a safe work environment, and creating a culture of continuous learning.
- JCI is a U.S.-based nonprofit that sets international standards for healthcare. Over 820 hospitals in 47 countries are JCI-accredited.
- The JCI accreditation process involves surveys to
MBC Support Group for Black Women – Insights in Genetic Testing.pdfbkling
Christina Spears, breast cancer genetic counselor at the Ohio State University Comprehensive Cancer Center, joined us for the MBC Support Group for Black Women to discuss the importance of genetic testing in communities of color and answer pressing questions.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...Ear Solutions (ESPL)
Binaural hearing using two hearing aids instead of one offers numerous advantages, including improved sound localization, enhanced sound quality, better speech understanding in noise, reduced listening effort, and greater overall satisfaction. By leveraging the brain’s natural ability to process sound from both ears, binaural hearing aids provide a more balanced, clear, and comfortable hearing experience. If you or a loved one is considering hearing aids, consult with a hearing care professional at Ear Solutions hearing aid clinic in Mumbai to explore the benefits of binaural hearing and determine the best solution for your hearing needs. Embracing binaural hearing can lead to a richer, more engaging auditory experience and significantly improve your quality of life.
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
3. 3
March 2022
Leverage pharmaceutical and medical device expertise to develop innovative products that
address needs in underserved therapeutic areas
Investment Highlights
Diversified revenue provides opportunities for continued growth
Commercial
XYOSTED® and NOCDURNA®
Commercial
Generic EpiPen®, Generic Forsteo®
(ROW), Sumatriptan and Makena®
Development
Teva (Generic Forteo® (US)),
Idorsia Pharmaceuticals
(selatogrel) and Pfizer
(undisclosed)
2021 revenue of $184.0M
(+23% vs. 2020)
2022 revenue guidance of
$200-220M*
(+18-30%** vs. 2021)
Gross margin at 63%
for the twelve months ended
December 31, 2021 as
proprietary products represent
43% of total revenue
Strong balance sheet with
$65.9 million in cash
and cash equivalents as of
December 31, 2021
Generated $36.6M
cash from operations
for the twelve months ended
December 31, 2021
Multiple opportunities for future value creation
Partner Business
Development
TLANDO®, ATRS-1901,
ATRS-1902 and ATRS-1903
Proprietary Products
* Revenue Guidance Excludes Unapproved Products **Excludes 2021 OTREXUP® Proprietary Revenue
4. 4
March 2022
Long-Term Growth Strategy
Expand Partnership Opportunities
A leader in self-administered injection technology
Support life-cycle management solutions
Disciplined Capital Allocation
Corporate development
In-licensing opportunities
Enhance Proprietary Portfolio
Support research and development
Leverage salesforce
Strong Financials
Drive operational efficiency
Increase margin profile and EPS
7. 7
March 2022
Patient-Centric Innovation Drives Strategy
Targeting two therapeutic areas with significant market opportunities
UROLOGY & ENDOCRINOLOGY
Focus on patient populations with
unmet needs
Target addressable physician audiences
for efficient commercialization
Identify and develop innovative,
differentiated assets
Leverage integrated capabilities
$13.3 $15.1 $17.9 $17.5
$39.2
$62.9
$80.0
$0.0
$10.0
$20.0
$30.0
$40.0
$50.0
$60.0
$70.0
$80.0
$90.0
2015 2016 2017 2018 2019 2020 2021*
Proprietary Revenue
(in millions)
* Includes OTREXUP® prior to asset sale to a subsidiary of Assertio Holdings
8. 8
Innovative self-delivery of testosterone (T)
replacement therapy for at-home use
• T levels maintained for as long as the
patient remains on therapy*
• Convenient, once-a-week dosing
• Virtually painless subcutaneous
injection
~75% of all commercial lives covered
18 Orange Book listed patents extending to
2038
XYOSTED®
(testosterone enanthate) for injection
Once Weekly Painless Steady PK Low Risk of Transfer
Please see Prescribing Information including important safety information and boxed warning.
In-Licensed:
TLANDO®
(testosterone undecanoate)
Granted tentative FDA approval in December
2020. Expect final FDA approval on PDUFA
target action date of March 28, 2022
2X/daily oral administration
First oral TRT without titration requirement
6 Orange Book listable patents pending final FDA
approval extending to 2030
Expect to launch in 2Q 2022 pending final FDA
approval
*Studied for 52 weeks when taken every week, as directed. Achieving desired blood levels may require dose adjustments at Week 7 based
upon Week 6 blood levels. Some patients fell below minimum level of 300 ng/dL despite dose adjustments.
9. 9
March 2022
Testosterone Market
Once
Weekly
Painless Efficacious Steady PK No Risk of Transfer
0
500,000
1,000,000
1,500,000
2,000,000
2,500,000
3,000,000
3,500,000
4,000,000
4,500,000
2021 TRT Growth: 5.1%
2021 TRT INJECTABLE Growth: 5.4%
2021 TRT Topical Growth: 0%
2021 TRT TRx: 8.0M
2021 TRT Injectable TRx: 5.9M
2021 TRT Topical TRx: 1.8M
IQVIA Data
11. 11
March 2022
• Branded TRT/IM and Desmopressin/OAB/BPH
• ~95% of TRT prescribers in the top 3 deciles is covered
• ~50%+ of NOCDURNA® targets are also XYOSTED® targets
• Every territory is covering 60 ATRS brand prescriber and 60-
90 targeted prescriber
Recently expanded sales team
• 122 FTE: 108 SAR, 12 RSM, 2 ASD
• 9 PSR: Flexible ‘virtual’ team for
patient services/tele detailing
Promotional allocation
• 70% XYOSTED®
• 30% NOCDURNA®
Target universe: ~16,000 Urology,
Endocrinology and PCP (select)
Focused Sales Effort to Optimize Current Portfolio
National Footprint
12. 12
March 2022
FDA-approved vasopressin analog indicated for the treatment of
nocturia due to nocturnal polyuria in adults who awaken at least two
times a night to void
• First and only sublingual tablet that targets the kidneys
• Short-acting desmopressin is underutilized due to poor disease
state and product awareness
Nocturia affects ~40 million adults in U.S.
~50%+ prescriber alignment overlap between NOCDURNA® and
XYOSTED®
Relaunched commercially in March 2021
In-Licensed:
NOCDURNA® (desmopressin acetate)
NOCDURNA® reduced nighttime voids by nearly half1
WOMEN
(N=118)
MEN
(N=102)
52% 43%
References: 1. NOCDURNA prescribing information: Ferring Pharmaceuticals Inc.
Please see Prescribing Information including important safety information and
boxed warning.
13. 13
March 2022
NOCDURNA® Works Quickly
A sublingual tablet that dissolves rapidly1
Administered without water1
Onset action occurs within 30 minutes1
Therapeutic effect as early as the first night1
Elimination from the body starts quickly, within
a half-life of 2.8 hours1
Antidiuretic effect lasts 6 hours1
Sublingual tablet formulation does not undergo
first-pass hepatic metabolism1
52% 43%
References: 1. NOCDURNA prescribing information: Ferring Pharmaceuticals Inc.
Please see Prescribing Information including important safety information and boxed warning.
* Source: Bloomberg/Symphony Health Solutions
0
100
200
300
400
500
600
700
800
NOCDURNA® Monthly TRx*
NRx Refills
14. 14
March 2022
ATRS-1901
Urology Asset
Antares Assets in Development
ATRS-1902 for Adrenal Crisis Rescue
Completed Pre-IND meeting with FDA
Filed IND with FDA in June 2021
Reported positive Phase I study results
Expect to conduct clinical PK and human
factor study in 2022
Target to file 505(b)(2) NDA with FDA by
YE 2022
ATRS-1903
Immunology Asset
ATRS-1902
Endocrinology Asset
ATRS-1901: Urology Asset
Completed Pre-IND meeting with FDA
Expect to conduct preclinical studies
Expect to conduct ex-U.S. clinical
dose-finding trial
ATRS-1903: Immunology Rescue Pen
Completed formulation
Expect to conduct ex-U.S. clinical
proof-of-concept trial
15. 15
March 2022
ATRS-1902 for Adrenal Crisis Rescue
+
62%
6%
6%
12%
14%
ENDOCRINOLOGY
PEDIATRICS
NURSE PRACTITIONER
PRIMARY CARE
ALL OTHERS
Solu-Cortef® Prescribers(4)
Simple (2-step), integrated device versus standard-of-care, Solu-Cortef®
sterile powder that requires reconstitution and multiple steps
Liquid stable formulation of hydrocortisone at room temperature
ATRS-1902 seeking indication for acute adrenal insufficiency, or adrenal
crisis, in adults and adolescents using Vai™, a novel proprietary auto-
injector platform to deliver hydrocortisone
Estimated ~140K U.S. patient population with adrenal insufficiency(1)(2)(3)
Endocrinology prescriber overlap with XYOSTED®
(1) Bornstein SR, AllolioB, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinicalpractice guideline. The Journal of ClinicalEndocrinologyand Metabolism. 2016;101(2):364–369.
(2) Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency.Lancet. 2014;383(9935):2152–2167.2of 3
(3) Chabre O, Goichot B, Zenaty D, Bertherat J. Group 1. Epidemiologyof primary and secondary adrenal insufficiency: prevalence and incidence, acute adrenal insufficiency, long-term morbidityand mortality. Annals of Endocrinology(Paris). 2017;78(6):490–494.
(4) IQVIA data
Phase I study results met its primary objective showing ATRS-1902
delivered a comparable PK profile to Solu-Cortef®. The study also
demonstrated that ATRS-1902 was safe and well tolerated.
Granted FDA Fast Track designation
16. 16
March 2022
Deep Device
Knowledge
Partner Business:
Extensive Regulatory
Expertise and
Success
Tailored Durable
Asset Development
PHARMACEUTICAL
TECHNOLOGY
PARTNER
$0.0
$20.0
$40.0
$60.0
$80.0
$100.0
$120.0
2015 2016 2017 2018 2019 2020 2021
Partner Product License and Development Royalties
$32.4
$46.1
$36.6
$37.1
$84.7 $86.7
$104.0
Partner Business Revenue
(in millions)
17. 17
March 2022
Commercial Experience
Teva’s Generic EpiPen
FDA-approved as therapeutically equivalent to
Mylan’s EpiPen® and fully substitutable at the
pharmacy
Antares receives cost plus margin on all devices
sold to Teva plus mid-to-high, single-digit
royalties on net sales
Teva garnered ~56%* share of EpiPen market
in 4Q 2021
*Calculated based on Bloomberg/Symphony Health Solutions
19. 19
March 2022
Teva launched ROW
12 European countries
Israel and Canada
Forteo® 2021 revenue
$441.6 million in U.S. by Lilly
$360.3 million in ROW by Lilly
Attractive economics to ATRS
Supply devices at reasonable margin
Royalties escalating to mid-teens
Potential FDA approval
Expect fully substitutable at pharmacy
Expect 6 month exclusivity
: Generic Forteo® (teriparatide)
20. 20
March 2022
Global Development Agreement with Idorsia Pharmaceuticals for
selatogrel, a New Chemical Entity, with the QuickShot® auto injector
selatogrel
Selatogrel is a potent
and highly selective
P2Y12 receptor
antagonist intended for
the treatment of
suspected Acute
Myocardial Infarction
(AMI)
Phase 2 data
demonstrated that
subcutaneous
administration of
selatogrel showed fast
and reversible
inhibition of platelet
aggregation in patients
Idorsia initiated global
Phase 3 study in June
2021
“SOS-AMI”
Selatogrel Outcome Study in
Acute Myocardial Infarction
Special Protocol
Assessment
Agreement
Granted fast track
designation
SUPPLY fully packaged product at cost plus margin and ROYALTIES escalating to low double digits
21. 21
March 2022
• ~800,000 occurrences of new
or recurrent MI1 annually
• 600,000 have a first MI +
200,000 have a recurrent MI
Myocardial Infarction Market Opportunity
1. Mozaffarian D et al. Circulation 2016
* American Heart Association
~8.4 million Americans*
have survived a Myocardial Infarction (MI)
Product Justification
to potentially change the way AMI is treated
Potent and highly selective antagonist of
P2Y12 receptor
“Fast” onset of action (within 15 min)
- for emergency use
- to quickly restore blood flow
- to keep heart muscle alive
- to stop heart attack process
“Short” duration of action
- limits bleeding risk
- to allow safe catherization and/or angioplasty
Easy to use and suitable for subcutaneous injection
- no HCP required to begin treatment
Safety demonstrated in Phase 2 results
22. 22
March 2022
Diversified Product Portfolio
Testosterone
Desmopressin Acetate
Sumatriptan
Epinephrine
Hydroxyprogesterone
Teriparatide
Testosterone
Teriparatide
P2Y12 Receptor Antagonist
Undisclosed
Hydrocortisone
Undisclosed
Undisclosed
XYOSTED®
NOCDURNA®
SUMATRIPTAN
EPINEPHRINE
MAKENA®
TERIPARATIDE (ROW)
TLANDO®
TERIPARATIDE (US)
SELATOGREL
UNDISCLOSED
ATRS-1902
ATRS-1901
ATRS-1903
PRODUCT MOLECULE PRECLINICAL CLINICAL FILED APPROVED MARKETED
COMPANY
Targeted investments designed to fuel growth through 2025 and beyond
***
*** Granted tentative FDA approval in December 2020
23. 50% 51%
59% 58%
63%
0%
10%
20%
30%
40%
50%
60%
70%
80%
2017 2018 2019 2020 2021
Gross Margin
$54.5M $63.6M
$123.9M
$149.6M
$184.0M
$200-220M*
2017 2018 2019 2020 2021 2022
+4%
vs. 2016
+21%
vs. 2019
+17%
vs. 2017
+95%
vs. 2018
Revenue Growth and 2022 Projections
Projected 5-Year CAGR of ~31%***
* Revenue Guidance Excludes Unapproved Products **Excludes 2021 OTREXUP® Proprietary Revenue ***Based on Mid-Point of 2022 Revenue Guidance
**** Adjusted net income is calculated by excluding the gain on sale of OTREXUP® in 2021, the deferred tax benefit net valuation allowance release in 2020, and the gain on sale of our needle-free product in 2018 and 2017 from net income
($16.7)
($6.5)
($2.0)
$56.2
$46.3
($17.6) ($19.0)
($2.0)
$6.9
$17.7
(25.0)
(15.0)
(5.0)
5.0
15.0
25.0
35.0
45.0
55.0
65.0
2017 2018 2019 2020 2021
Net Income and Adjusted Net Income****
(in millions)
Net Income (Loss)
Adjusted Net Income (Loss)
+23%
vs. 2020
+18-30%**
vs. 2021
22% 19% 9% 7% 8%
58% 58%
50%
42% 40%
0%
20%
40%
60%
80%
100%
2017 2018 2019 2020 2021
R&D and SG&A as % of Total Revenue
R&D SG&A
24. 24
March 2022
2022 Invest and Grow Strategy
Internal
Pipeline
Expansion
Commercial
Expansion of
Organizational
Structure and
Capabilities
Corporate
Development
New scalable structure to
support future growth
Efficient and scalable
Leveraging resources to
accelerate opportunities
New candidates and
accelerated screening
25. 25
March 2022
Antares Pharma: Long-Term Value Proposition
Diverse portfolio of
commercialized products
Multiple growth drivers
• Continued XYOSTED® prescription growth
• Continued generic EpiPen® prescription growth
• NOCDURNA® prescription growth
• Pending FDA approval and commercial launch of
TLANDO®
• Potential FDA approval and U.S. launch of Teva’s
generic teriparatide
• Pfizer development program
• Idorsia’s selatogrel rescue pen development
program
Proprietary R&D portfolio
• ATRS-1902 for adrenal crisis rescue
• ATRS-1901 for urology
• ATRS-1903 for immunology
Disciplined capital allocation
• Invest to diversify portfolio
Expanding operational capabilities